Raymond E. Cabillot Sells 5,381 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 5,381 shares of the stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $41.64, for a total transaction of $224,064.84. Following the completion of the transaction, the director now directly owns 319,752 shares of the company’s stock, valued at $13,314,473.28. This trade represents a 1.66 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Pro-Dex Stock Up 1.3 %

Shares of Pro-Dex stock traded up $0.52 on Tuesday, reaching $41.79. 20,432 shares of the company were exchanged, compared to its average volume of 27,696. Pro-Dex, Inc. has a one year low of $16.18 and a one year high of $59.60. The company has a current ratio of 3.41, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36. The company has a 50-day moving average of $47.75 and a 200 day moving average of $34.11. The company has a market capitalization of $136.24 million, a price-to-earnings ratio of 27.14 and a beta of 0.56.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP boosted its stake in shares of Pro-Dex by 5.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock valued at $1,238,000 after purchasing an additional 3,067 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Pro-Dex by 9.1% in the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after acquiring an additional 2,296 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after purchasing an additional 529 shares during the last quarter. Bard Associates Inc. grew its holdings in Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after acquiring an additional 2,031 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in Pro-Dex by 7.9% in the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after buying an additional 900 shares during the period. 15.28% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on PDEX shares. StockNews.com upgraded Pro-Dex from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 14th. Ascendiant Capital Markets raised their price target on Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, November 11th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.